证券日报网讯 2月26日，赛伦生物发布公告称，公司2025年实现营业总收入19620.59万元，同比增长 0.66%；归属于母公司所有者的净利润5171.35万元，同比增长16.76%。 （文章来源：证券日报） ...

2025年度，公司营业收入微增，毛利率基本持平。2025年下半年挂网上市的抗狂犬病血清处于上市销售 初期，尚未在报告期形成显著收入贡献。本期净利润同比增长，主要系2024年度公司对联营企业上海赛 远生物科技有限公司确认了投资亏损并对长期股权投资余额全额计提减值准备，以及本期非经常性损益 同比减少、研发费用同比减少等因素综合影响所致。 智通财经APP讯，赛伦生物(688163.SH)发布2025年度业绩快报，2025年度实现营业总收入1.96亿元，同 比增长0.66%;实现归属于母公司所有者的净利润5171.35万元，同比增长16.76%。 ...

2025年度，公司营业收入微增，毛利率基本持平。2025年下半年挂网上市的抗狂犬病血清处于上市销售 初期，尚未在报告期形成显著收入贡献。本期净利润同比增长，主要系2024年度公司对联营企业上海赛 远生物科技有限公司确认了投资亏损并对长期股权投资余额全额计提减值准备，以及本期非经常性损益 同比减少、研发费用同比减少等因素综合影响所致。 格隆汇2月26日丨赛伦生物(688163.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入 19,620.59万元，同比增长0.66%；实现营业利润6,204.00万元，同比增长19.34%；实现利润总额6,173.91 万元，同比增长22.10%；实现归属于母公司所有者的净利润5,171.35万元，同比增长16.76%；实现归属 于母公司所有者的扣除非经常性损益的净利润4,255.89万元，同比增长50.65%。 ...

注：1、本报告期初数同法定披露的上年年末数。 2、以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司 2025 年年度报告为准。数据若有尾差，为四舍五入所致。 1 证券代码：688163 证券简称：赛伦生物 公告编号：2026-001 上海赛伦生物技术股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以上海赛伦生物技术股份有限公司（以下简称"公司"）2025 年 年度报告中披露的数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 币种：人民币 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 19,620.59 | 19,491.59 | 0.66 | | 营业利润 | 6,204.00 | 5,198.49 | 19.34 | | 利润总额 | 6,173.91 ...

经济观察网赛伦生物近期融资活动活跃，主力资金流向有所变化，公司基本面保持稳定，医药生物板块 整体受到政策支持。 资金动向 融资活动活跃：2026年1月22日，赛伦生物获融资买入161.25万元，融资余额达1.51亿元，占流通市值的 5.54%，融资余额处于近一年较高水平。同日股价上涨0.36%，成交额2862.24万元。 主力资金流向变化：2026年1月9日，主力资金净流入97.94万元，较前一交易日由流出转为流入，同期 医药生物板块上涨1.58%，可能反映短期市场情绪回暖。更早的1月6日也曾出现主力资金净流入112.76 万元的现象。 历史季度业绩：2025年第一季度报告显示，归母净利润375.73万元，同比增长154.77%，但营业总收入 同比下降2.59%。 公司状况 ESG评级更新：华证指数2025年10月31日评级中，赛伦生物ESG评级为CCC，在生物科技行业中排名第 63位，环境(E)项得分较低。 行业政策现状 医药生物板块整体受政策支持及人口老龄化趋势驱动，2026年1月初板块表现较强，可能间接影响个股 资金流向。公司主营业务聚焦抗血清抗毒素领域，产品线单一但细分市场壁垒较高。 以上内容基于公开 ...

（编辑 楚丽君） 证券日报网讯 1月30日，赛伦生物在互动平台回答投资者提问时表示，公司第四季度营业收入较低，从 而影响了单季度利润。主要原因系公司主要产品抗蛇毒血清和马破伤风免疫球蛋白的适应症发生率具有 显著的季节性，蛇伤、外伤均在夏季高发，第二、三季度销量较大，第一、四季度销量较小，各季度的 销售收入随之呈现出显著的季节性起伏。公司将结合自身发展需求及外部环境条件，持续关注并积极寻 求优质的并购标的，促进公司主业的外延式发展。公司严格遵循信息披露法规，若有明确并购计划且达 到信息披露标准，将严格按照相关规定及时履行信息披露义务，相关信息请以公司对外披露的公告为 准。 ...

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Core Viewpoint - The company is developing a broad-spectrum anti-snake venom antibody using new antibody technology, aiming to create an innovative drug that is universal, has fewer side effects, and is more convenient for use [1] Group 1: Company Development - The company is focused on developing innovative drugs to meet clinical needs in snakebite treatment [1] - The new antibody technology is expected to complement existing anti-snake venom serum, enhancing treatment options [1] - The goal is to improve the company's long-term competitiveness in the field of snakebite diseases [1]

Core Viewpoint - The company, Sairun Biotech, is currently the only domestic player developing antivenom serum for snake bites and is focusing on innovative broad-spectrum antibody technology to maintain its market leadership and address potential competition [1] Group 1: Company Strategy - Sairun Biotech is developing broad-spectrum antivenom antibodies using new antibody technology aimed at creating innovative drugs that are more universal, have fewer side effects, and are easier to administer [1] - The company aims to complement existing antivenom serums with its innovative products to better meet clinical medication needs in various application scenarios [1] Group 2: Market Position - Sairun Biotech acknowledges the presence of four types of venomous snakes in the market but emphasizes its first-mover advantage and technological barriers to sustain its competitive edge [1] - The company is aware of the potential for new entrants in the antivenom serum market and is strategizing to leverage its existing advantages [1]

Core Viewpoint - SAILUN Biotech is actively developing multiple innovative biopharmaceuticals and snake venom rapid diagnostic test projects, which are currently in the research and development stage [2] Group 1 - The company has confirmed that aside from its already listed products, it is focusing on several innovative biopharmaceuticals and diagnostic tests [2] - The company encourages stakeholders to pay attention to its annual report and the annual "quality improvement and efficiency enhancement" action plan for insights into its business strategy and development plans [2]